We have changed our visitation policy for the safety of our patients and staff. Click here for the updated visitation policy and click here for information about COVID-19.

[LCID Study Number: 20193116]

A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects with Guillain Barré Syndrome

This study aims to evaluate the safety and tolerability of ANX005 when administered in combination with IVIg in GBS subjects

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-8383